An exciting day for Korecyte Bio! We have finalised a commercial contract with @KingsCollegeLon to pursue hypoxia-sensing #CART #Immunotherapy. A technology for treating solid cancers while avoiding off-tumour activation to lower toxicities for CAR-T.
The King’s article can be found here: https://www.kcl.ac.uk/news/kings-signs-commercial-contract-with-cellular-immunotherapy-startup-korecyte-bio
